The global liver fibrosis treatment market is expected to surpass an impressive valuation of USD 16.43 billion in 2023 and is projected to exhibit a CAGR of 11% from 2023 to 2033. The primary factors of death and morbidity in individuals with liver cirrhosis are liver fibrosis and, in specific, cirrhosis. Their intervention or reversal has emerged as critical access points in clinical trials involving innovative liver-specific stimulants.
In persistent hepatitis B and C, significant advancements have been made with treatments that effectively address the consequence of fundamental liver damage. In the proportion of patients, extremely effective suppressive therapy can control strategies or even generate reversal, but this treatment remains elusive for the vast bulk of liver patients suffering from advanced alcoholic or nonalcoholic steatohepatitis, and genetic or immune deficiency liver failure.
Implementation for patients with liver fibrosis and personalized treatment is inextricably linked to the emergence of noninvasive fibrosis, fibrogenesis, and fibrosis biomarkers, which will continue to lead the industry. Cirrhosis is the 12th primary factor of death in the United States. Latest research has shown that liver fibrosis is a continual process and that initial cirrhosis may be recoverable. As a result, the treatment for liver fibrosis is expected to grow significantly over the next decades. Although liver biopsy is still the fundamental basis, transient elastography has become increasingly widely available and is quickly replacing biopsy as the preferred option for liver fibrosis staging which is contributing to the market expansion.
Furthermore, rising cancer cases, including liver cancer, are anticipated to propel the expansion of the global chronic liver disease therapeutic industry, contributing to market growth. For instance, the American Cancer Society estimates that 41,260 suspected cases of primary liver cancer were diagnosed in the United States in 2022 (28,600 in men and 12,660 in women).
Rising the number of various forms of chronic liver diseases is driving the market growth. For instance, Primary Sclerosing Cholangitis (PSC) is a chronic illness in which the bile ducts inside and outside the liver get to be sore and disfigured, ultimately narrowing and blocking, and causing liver damage. Based on the National Institute of Health, nonalcoholic fatty liver disease (NAFLD) represents the most prevalent liver disease, accounting for 25% of all cases worldwide. NAFLD and its variant, nonalcoholic steatohepatitis, influence 30% and 5% of the people in the United States, respectively. Therefore, treatment for liver fibrosis is expected to grow significantly in this country.
Hepatitis C therapeutics are becoming more widely used among healthcare professionals in the United States, and a growing number of patients are receiving them. This, integrated with a robust R&D pipeline and the introduction of novel medicines in the United States, is accelerating the expansion of the hepatitis C treatment marketplace in North America. For instance, in April 2019, the USA Food and Drug Administration approved Mavyret by AbbVie as the first-ever treatment affirmed for pediatric Hepatitis C patients of all genotypes. As a result of these factors, the Liver Fibrosis Treatment Market is expected to grow in the coming decades.
The high incidence of Nonalcoholic steatohepatitis (NASH) also affects the population, fueling the market growth. NASH affects approximately 3% to 6% of the USA inhabitants, and the pervasiveness is rising. Although there are several noninvasive screening and rating systems available to characterize NAFLD and NASH, liver biopsy is the only acceptable form for diagnosing NASH. Presently, the USA Food and Drug Administration has not approved any NASH-specific therapies.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 16.43 billion |
| Anticipated Forecast Value (2033) | USD 46.65 billion |
| Projected Growth Rate (2023 to 2033) | 11% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The COVID-19 pandemic had an adverse effect on the global liver fibrosis therapeutics market, as the demand for medications used in liver rehabilitation decreased. Based on the National Center for Biotechnology Information, COVID-19 therapy in January 2020 involves discussing and parenterally administered agents, antivirals, immunomodulatory medicines, anti-cytokines, monoclonal antibodies, and miscellaneous agents. As a result, drugs demonstrated for use in other disease conditions have been produced in smaller quantities than those used in COVID-19 treatment. From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.
The rise in the prevalence of adverse outcomes such as patients with hepatitis B or C virus infection, a suppressed immune system owing to co-infection with human immunodeficiency virus (HIV), and the usage of immunosuppressive medicines after a liver transplant are poised to drive growth in the liver fibrosis treatment market over the forecast period. For instance, as per World Health Organization data released in 2022, 296 million individuals were estimated to be residing with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Hepatitis B caused an estimated 820 000 deaths in 2019, the majority of which were caused by cirrhosis and hepatocellular carcinoma.
Funding Approaches by multiple private research organizations to Drive Market
The increased research carried out by several private research organizations to develop treatments for liver fibrosis and other fatty liver diseases are anticipated to increase growth in the liver fibrosis treatment market. For instance, in August 2018, Virginia Tech's College of Science and the University of Virginia's Department of Pharmacology garnered USD 400,000 in funding from the Virginia Biosciences Health Research Corporation (VBHRC), with Continuum Biosciences, Inc. matching funds. This grant, combined with matching funds, would assist scientists in creating drugs to treat nonalcoholic steatohepatitis (NASH).
Research and studies to evolve novel treatment therapies in liver fibrosis disease drive market growth
Expanding pre-clinical and clinical studies and development by prominent stakeholders to establish innovative treatment options in the liver fibrosis regime are predicted to propel the worldwide liver fibrosis treatment's future growth. For instance, the USA Food and Drug Administration permitted Orphan Drug Designation to PTG-300, a subcutaneous injectable evolved by Protagonist Therapeutics, Inc., in March 2018. The PTG-300 is presently in a medical study for the treatment of beta-thalassemia and can also be employed to cure liver fibrosis.
Principal Consultant
High Costs to Hinder Market Growth
The massive cost necessary for drug assessment of the liver disease therapeutic process is one of the key factors impeding the expansion of the global liver fibrosis treatment market. According to the Centers for Disease Analysis, the United States invests USD 5 billion per year on disease-related healthcare costs like chemotherapy, transplants, screening, and hospitalizations.
The accessibility of a variety of Innovative Drug Molecules drive Asia Pacific market
Owing to the availability of a variety of novel drug molecules to improve the treatment process and technological development in rehabilitation in this region, North America leads the liver fibrosis market. Furthermore, surging medical spending and the emergence of major important players will speed up the market's pace of growth in this region. The mortality rate from liver diseases has increased, as has the occurrence of liver cancer.
Non-alcoholic fatty liver disorder (NAFLD) affects approximately 20% of Canadians, based on the Canadian Liver Foundation. Obesity is the primary factor of fatty liver disease in Canada. In 2018, nearly 30% of Canadians aged 18 and up reported being overweight or obese based on their height and weight.
Increasing Prevalence of Liver Fibrosis is Spurring Demand for Liver Fibrosis Treatment
Asia Pacific is predicted to expand during the forthcoming years owing to the rising incidence of liver fibrosis in this region. Moreover, the advancement of medical infrastructure and soaring regulatory reforms will enhance the industry's pace of growth in this region. During the projected period, the Asia Pacific market is projected to show the highest CAGR of 11.1%.
There is a growing patient pool of hepatitis C patients in developing nations like China, India, and other South-East Asian countries. Nevertheless, the patient population is dependent on the various governments for subsidized drugs, and earnings contribution is lesser; moreover, due to such aspects, the market in the Asia Pacific is growing rapidly.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospital Segment is Estimated to Hold the Largest Share
Based on end user, the global liver fibrosis treatment market is segmented into hospital, and Specialty Clinics. The hospital segment held the largest share of the market in 2021. Moreover, the same segment is expected to register the highest CAGR from 2022 to 2033.
Hepatotropic drug segment led the market in historical period
With a market share of 29.5% in 2021, the hepatotropic drug segment led the market. This increase is attributed to increased awareness of new drugs. Furthermore, hepatitis is a medical condition that primarily affects the liver, eventually contaminating the digestion process and the brain. HCV, HBV, and HAV are the three major types of hepatitis conditions. HCV is a major public health problem in which the liver becomes inflamed as a result of infection. As a result, this segment is expected to grow rapidly.
Key players in the Liver Fibrosis Treatment market are Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., Inventiva Pharma, Pharmaxis Limited.
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | USD 2.5 billion |
| Market Value in 2033 | USD 46.65 billion |
| Growth Rate | CAGR of 11% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment Type, Condition, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Gilead Sciences, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb; Johnson and Johnson; Novartis AG; Vertex Pharmaceuticals Incorporated; Pfizer Inc.; FibroGen, Inc.; Inventiva Pharma; Pharmaxis Limited |
| Customization | Available Upon Request |
The market is estimated to reach USD 46.65 billion by 2033.
Gilead Sciences, Inc., Merck & Co., Inc., and Bristol-Myers Squibb are key market players.
The market is forecasted to register a CAGR of 11% through 2033.
Asia Pacific is likely to expand at a CAGR of 11.1% through 2033.
The hospital sector held a significant share in 2021.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 5.1. Peroxisome Proliferator-activated Receptors (PPAR)-alpha Agonist 5.2. ACE Inhibitors 5.3. Hepatotropic Drug 5.4. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Condition 6.1. Chronic Liver Diseases 6.2. Hepatitis C 6.3. Nonalcoholic Steatohepatitis 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Hospitals 7.2. Specialty Clinics 7.3. Others 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Gilead Sciences, Inc. 16.2. Merck & Co., Inc. 16.3. Bristol-Myers Squibb 16.4. Johnson and Johnson 16.5. Novartis AG 16.6. Vertex Pharmaceuticals Incorporated 16.7. Pfizer Inc. 16.8. FibroGen, Inc. 16.9. Inventiva Pharma 16.10. Pharmaxis Limited 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Liver Fibrosis Treatment Market
